Evidence map›Paper›PMID 24027433›Full record

ArticleNeoplasia (New York, N.Y.)2013

MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer.

Tommaso Colangelo, Alessandra Fucci, Carolina Votino, Lina Sabatino, Massimo Pancione, Carmelo Laudanna, Monica Binaschi, Mario Bigioni, Carlo Alberto Maggi, Domenico Parente and 2 more

Open access · goldAbstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 2 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 2 syntheses or guidelines pooled it, 141 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Protective Effects of PPAROxidative medicine and cellular longevity · 2022
    Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. MicroRNA-130b functions as an oncogene and is a predictive marker of poor prognosis in lung adenocarcinoma.Laboratory investigation; a journal of technical methods and pathology · 2021
    Article
  19. Article
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Tommaso ColangeloDepartment of Sciences and Technologies, University of Sannio, Benevento, Italy.
Alessandra Fucci
Carolina Votino
Lina Sabatino
Massimo Pancione
Carmelo Laudanna
Monica Binaschi
Mario Bigioni
Carlo Alberto Maggi
Domenico Parente
Nicola Forte
Vittorio Colantuoni
University of Sannio · ITMenarini Group (Italy) · ITFatebenefratelli Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNA-130b (miR-130b) is involved in several biologic processes; its role in colorectal tumorigenesis has not been addressed so far. Herein, we demonstrate that miR-130b up-regulation exhibits clinical relevance as it is linked to advanced colorectal cancers (CRCs), poor patients' prognosis, and molecular features of enhanced epithelial-mesenchymal transition (EMT) and angiogenesis. miR-130b high-expressing cells develop large, dedifferentiated, and vascularized tumors in mouse xenografts, features that are reverted by intratumor injection of a specific antisense RNA. In contrast, injection of the corresponding mimic in mouse xenografts from miR-130b low-expressing cells increases tumor growth and angiogenic potential while reduces the epithelial hallmarks. These biologic effects are reproduced in human CRC cell lines. We identify peroxisome proliferator-activated receptor γ (PPARγ) as an miR-130b direct target in CRC in vitro and in vivo. Notably, the effects of PPARγ gain- and loss-of-function phenocopy those due to miR-130b down-regulation or up-regulation, respectively, underscoring their biologic relevance. Furthermore, we provide mechanistic evidences that most of the miR-130b-dependent effects are due to PPARγ suppression that in turn deregulates PTEN, E-cadherin, Snail, and vascular endothelial growth factor, key mediators of cell proliferation, EMT, and angiogenesis. Since higher levels of miR-130b are found in advanced tumor stages (III-IV), we propose a novel role of the miR-130b-PPARγ axis in fostering the progression toward more invasive CRCs. Detection of onco-miR-130b and its association with PPARγ may be useful as a prognostic biomarker. Its targeting in vivo should be evaluated as a novel effective therapeutic tool against CRC.

Indexed as

AnimalsBiomarkers, TumorCadherinsCell Line, TumorCell ProliferationCell Transformation, NeoplasticColorectal NeoplasmsDown-RegulationEpithelial-Mesenchymal TransitionFemaleHCT116 CellsHumansMiceMice, NudeMicroRNAsNeoplasm InvasivenessBiomarkers, TumorCadherinsMicroRNAsMIRN130 microRNA, humanPPAR gammaPTEN PhosphohydrolasePTEN protein, humanSnail Family Transcription FactorsTranscription FactorsVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID24027433
PMCPMC3769887
OpenAlexW1781296532

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.